Brief: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial Of ‘Armored’ Car T Therapy For Ovarian Cancer
01/10/2026 12:05
BRIEF-Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial Of ‘Armored’ Car T Therapy For Ovarian Cancer Oct 1 (Reuters) - Generate Biomedicines Inc GENB.O:
ROSWELL PARK, GENERATE BIOMEDICINES LAUNCH EXCLUSIVE CLINICAL TRIAL OF ‘ARMORED’ CAR T THERAPY FOR OVARIAN CANCER
GENERATE BIOMEDICINES - GB-5267 TREATMENT DESIGNED TO AVOID PRE-INFUSION CHEMOTHERAPY
GENERATE BIOMEDICINES - GB-5267 TARGETS MUC16 BIOMARKER IN OVER 80% OF OVARIAN TUMORS
Source text: ID:nGNX4qcpLT
Further company coverage: GENB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Generate Biomedicines
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)
Brief: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases
Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports
Brief: Zealand Pharma Makes Deal With Generate Worth Up To $1.2 Billion - Bloomberg News